JAGUAR HEALTH, INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- JAGUAR HEALTH, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2024-09-30 was $2.65M.
- JAGUAR HEALTH, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2018-12-31 was $0.00.
- JAGUAR HEALTH, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2018-09-30 was $203.41K.
- JAGUAR HEALTH, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2018-06-30 was $203.41K.
- JAGUAR HEALTH, INC. stock issued during period, value, conversion of convertible securities for fiscal 2019 was $48.80K, a 96.96% decline from fiscal 2018.
- JAGUAR HEALTH, INC. stock issued during period, value, conversion of convertible securities for fiscal 2018 was $1.61M, a 78.53% increase from fiscal 2017.
- JAGUAR HEALTH, INC. stock issued during period, value, conversion of convertible securities for fiscal 2017 was $900.36K.
- JAGUAR HEALTH, INC. stock issued during period, value, conversion of convertible securities for fiscal 2015 was $7.65M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2024-09-30 | $2.65M 10-Q · filed 2024-11-13 | |
| 2019-12-31 | $48.80K 10-K · filed 2020-04-03 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-03 | $1.61M 10-K · filed 2020-04-03 |
| 2018-09-30 | $203.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | |
| 2018-06-30 | $203.41K 10-Q · filed 2019-08-14 | |
| 2018-03-31 | $1.40M 10-Q · filed 2019-05-21 | |
| 2017-12-31 | $900.36K 10-K · filed 2019-04-10 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $7.65M 10-K · filed 2017-02-15 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | |
| 2014-12-31 | $525.00K 10-Q · filed 2015-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |